Hussein M, Salah D, Ayman M. Therapeutic impact of telomerase inhibitor imetelstat: a literature review. Int J Adv Health Sci Technol. 2023;3(2):111–7.

Article  Google Scholar 

Geron Corporation. Form 10-K 2024. https://ir.geron.com/. Accessed 26 Jun 2024

Majidi F, Gattermann N. Imetelstat: finally a disease-modifying treatment for lower-risk myelodysplastic syndromes? Med. 2024;5(3):184–6.

Article  PubMed  CAS  Google Scholar 

Platzbecker U, Santini V, Fenaux P, et al. Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024;403(10423):249–60.

Article  PubMed  CAS  Google Scholar 

Wang X, Hu CS, Petersen B, et al. Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells. Blood Adv. 2018;2(18):2378–88.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Geron Corporation. Imetelstat: US prescribing information. 2024. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. Accessed 24 Jun 2024.

Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703–19.

Article  PubMed  PubMed Central  Google Scholar 

Bănescu C, Tripon F, Muntean C. The genetic landscape of myelodysplastic neoplasm progression to acute myeloid leukemia. Int J Mol Sci. 2023. https://doi.org/10.3390/ijms24065734.

Article  PubMed  PubMed Central  Google Scholar 

Chifotides HT, Masarova L, Verstovsek S. SOHO state of the art updates and next questions: novel therapeutic strategies in development for myelofibrosis. Clin Lymphoma Myeloma Leuk. 2023;23(4):219–31.

Article  PubMed  PubMed Central  Google Scholar 

Volpe VO, Garcia-Manero G, Komrokji RS. SOHO state of the art updates and next questions: treatment of lower risk myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk. 2023;23(3):168–77.

Article  PubMed  CAS  Google Scholar 

US Food & Drug Administration. FDA approves imetelstat for low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia [media release]. 6 Jun 2024. https://www.fda.gov/.

Geron Corporation. Geron announces FDA approval of RYTELO™ (imetelstat), a first-in-class telomerase inhibitor, for the treatment of adult patients with lower-risk MDS with transfusion-dependent anemia [media release]. 6 Jun 2024. https://ir.geron.com/.

Herbert BS, Gellert GC, Hochreiter A, et al. Lipid modification of GRN163, an N3’–>P5’ thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene. 2005;24(33):5262–8.

Article  PubMed  CAS  Google Scholar 

Gryaznov SM, Jackson S, Dikmen G, et al. Oligonucleotide conjugate GRN163L targeting human telomerase as potential anticancer and antimetastatic agent. Nucleosides Nucleotides Nucleic Acids. 2007;26(10–2):1577–9.

Article  PubMed  CAS  Google Scholar 

Mosoyan G, Kraus T, Ye F, et al. Imetelstat, a telomerase inhibitor, differentially affects normal and malignant megakaryopoiesis. Leukemia. 2017;31(11):2458–67.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Thompson CAH, Gu A, Yang SY, et al. Transient telomerase inhibition with imetelstat impacts DNA damage signals and cell-cycle kinetics. Mol Cancer Res. 2018;16(8):1215–25.

Article  PubMed  CAS  Google Scholar 

Hidaka D, Onozawa M, Miyashita N, et al. Short-term treatment with imetelstat sensitizes hematopoietic malignant cells to a genotoxic agent via suppression of the telomerase-mediated DNA repair process. Leuk Lymphoma. 2020;61(11):2722–32.

Article  PubMed  CAS  Google Scholar 

Barwe SP, Huang F, Kolb EA, et al. Imetelstat induces leukemia stem cell death in pediatric acute myeloid leukemia patient-derived xenografts. J Clin Med. 2022. https://doi.org/10.3390/jcm11071923.

Article  PubMed  PubMed Central  Google Scholar 

Bruedigam C, Porter AH, Song A, et al. Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemia. Nat Cancer. 2024;5(1):47–65.

Article  PubMed  CAS  Google Scholar 

Baerlocher GM, Rusbuldt J, Bussolari J, et al. Myelosuppression in patients treated with the telomerase inhibitor imetelstat is not mediated through activation of Toll-like receptors. Int J Mol Sci. 2020. https://doi.org/10.3390/ijms21186550.

Article  PubMed  PubMed Central  Google Scholar 

Lennox A, Huang F, Behrs MK, et al. Clinical pharmacology of imetelstat, a first-in-class oligonucleotide telomerase inhibitor [abstract no. PII-050]. Clin Pharmacol Therap. 2024;115(S1):S64.

Google Scholar 

Kazmi F, Sensenhauser C, Greway T. Characterization of the in vitro inhibitory potential of the oligonucleotide imetelstat on human cytochrome P450 enzymes with predictions of in vivo drug-drug interactions. Drug Metab Dispos. 2019;47(1):9–14.

Article  PubMed  CAS  Google Scholar 

Steensma DP, Fenaux P, Van Eygen K, et al. Imetelstat achieves meaningful and durable transfusion independence in high transfusion-burden patients with lower-risk myelodysplastic syndromes in a phase II study. J Clin Oncol. 2021;39(1):48–56.

Article  PubMed  CAS  Google Scholar 

Mascarenhas J, Komrokji RS, Palandri F, et al. Randomized, single-blind, multicenter phase II study of two doses of imetelstat in relapsed or refractory myelofibrosis. J Clin Oncol. 2021;39(26):2881–92.

Article  PubMed  CAS  Google Scholar 

Tefferi A, Lasho TL, Begna KH, et al. A pilot study of the telomerase inhibitor imetelstat for myelofibrosis. N Engl J Med. 2015;373(10):908–19.

Article  PubMed  CAS  Google Scholar